Browsing by Author Branford, Susan

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 4 of 4
Issue DateTitleAuthor(s)Citation
2013Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CMLHertzberg, Mark; Altamura, Haley K; Branford, Susan; et al, Various; Field, Chani R; Georgievski, Jasmina; Jamison, Bronte A; Phillis, Stuart; Prime, Jodi A; Ross, David M; Yeoman, Alexandra L; Yeung, David; Western Clinical School: Medicine (Westmead)Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML, Blood, vol.121, 19, 2013,pp 3818-3824
2003Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly disgnosed chronic myeloid leukemia in chronic phaseBradstock, Kenneth; Arthur, C.; Branford, Susan; Browett, Peter; Durrant, Simon; Gathmann, I.; Grigg, Andrew P.; Harper, A.; Hughes, T. P.; Joske, D.; Lynch, Kevin; Ma, D.; Rudzki, Zbigniew; Schwarer, Anthony; Seymour, John F.; Taylor, Kerry; Western Clinical School: Westmead Millennium InstituteImatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly disgnosed chronic myeloid leukemia in chronic phase, Leukemia, vol.17,(12),2003,pp 2401-2409
2004Real-Time Quantitative Pcr Analysis Can Be Used As A Primary Screen To Identify Patients With Cml Treated With Imatinib Who Have Bcr-Abl Kinase Domain Mutations.Bradstock, Kenneth; Branford, Susan; Browett, Peter; Durrant, Simon; et, al; Grigg, Andrew P.; Parkinson, Ian; Rudzki, Zbigniew; Schwarer, Anthony; Seymour, John F.; Taylor, Kerry; Western Clinical School: Westmead Millennium InstituteReal-Time Quantitative Pcr Analysis Can Be Used As A Primary Screen To Identify Patients With Cml Treated With Imatinib Who Have Bcr-Abl Kinase Domain Mutations., Blood, vol.104,(9),2004,pp 2926-2932
2015TIDEL-II: frontline use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targetsHertzberg, Mark; Taper, John; Trotman, Judith; Braley, Jodi; Branford, Susan; et al, Various; Herschtal, Alan; Hiwase, Devendra K; Issa, Samra; Kornhauser, Michael; Osborn, Michael P; Schwarer, Anthony; White, Deborah L; Yeung, David T; Western Clinical School: Medicine (Westmead); Medicine; Concord Clinical School: MedicineTIDEL-II: frontline use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets, Blood, vol.125, 6, 2015,pp 915-923